Browse Studies — Arctuva

Phase 3

Kidney Transplant Preemptive Therapy or Prophylaxis (KPoP) for CMV Prevention in D+R- Recipients

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease …

Cytomegalovirus (CMV)Kidney Transplant; ComplicationsKidney Diseases

Estimated

~$10 – $5,625

University of California, San FranciscoNCT06798909

Phase 1

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Higher Dose of the HCMV-HIV Vaccine Candidate VIR-1388, in HCMV-seropositive Adult Participants Without HIV

This study is to test an experimental HIV Vaccine. About 12 participants, aged 18-55 years and who already have cytomegalovirus (CMV) will take part in this st…

Cytomegalovirus (CMV)HIV (Human Immunodeficiency Virus)

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT07801456

Phase 2

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

The goal of this clinical trial is to compare antiviral treatment strategies for cytomegalovirus (CMV) anterior uveitis - a viral infection causing inflammatio…

Cytomegalovirus (CMV)Anterior UveitisInfectious Uveitis+1 more

Estimated

~$10 – $5,625

University of California, San FranciscoNCT07513623

Phase 3

A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and te…

Cytomegalovirus (CMV)

Estimated

~$10 – $7,500

TakedaNCT05319353